Nicotine
Habitrol, Nicoderm Cq, Nicotrol (nicotine) is a small molecule pharmaceutical. Nicotine was first approved as Nicotrol on 1996-03-22. It is used to treat tobacco use disorder and ulcerative colitis in the USA. It is known to target transient receptor potential cation channel subfamily A member 1, P2Y purinoceptor 11, hydroxycarboxylic acid receptor 1, neuronal acetylcholine receptor subunit alpha-4, hydroxycarboxylic acid receptor 2, transient receptor potential cation channel subfamily M member 2, potassium voltage-gated channel subfamily D member 3, neuronal acetylcholine receptor subunit alpha-9, hydroxycarboxylic acid receptor 3, neuronal acetylcholine receptor subunit alpha-10, and neuronal acetylcholine receptor subunit alpha-3.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Habitrol, Nicoderm cq, Nicotrol (generic drugs available since 1997-10-20, discontinued: Prostep)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| tobacco use disorder | — | D014029 | F17 |
| ulcerative colitis | EFO_0000729 | D003093 | K51 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
811 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | F17 | 46 | 52 | 23 | 32 | 87 | 226 | |
| Smoking cessation | D016540 | EFO_0004319 | 29 | 29 | 19 | 47 | 69 | 185 | |
| Smoking | D012907 | EFO_0003768 | F17 | 16 | 14 | 12 | 27 | 55 | 117 |
| Cigarette smoking | D000073865 | 11 | 17 | 3 | 7 | 25 | 58 | ||
| Tobacco use cessation | D020340 | 2 | 4 | 4 | 10 | 11 | 28 | ||
| Tobacco use | D064424 | Z72.0 | 4 | 1 | 3 | 2 | 19 | 28 | |
| Tobacco smoking | D000073869 | 2 | 3 | 2 | 9 | 12 | 27 | ||
| Vaping | D000072137 | 1 | 3 | 1 | 4 | 18 | 27 | ||
| Schizophrenia | D012559 | EFO_0000692 | F20 | 5 | 5 | — | 8 | 7 | 24 |
| Lung neoplasms | D008175 | C34.90 | 2 | — | 4 | 1 | 9 | 16 |
Show 34 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | — | 1 | 1 | — | 5 | 7 | |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | 1 | 1 | — | 1 | 3 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | — | 2 | 3 | |
| Covid-19 | D000086382 | U07.1 | — | — | 2 | — | — | 2 | |
| Disease | D004194 | EFO_0000408 | R69 | — | — | 2 | — | — | 2 |
| Habits | D006184 | — | 1 | 1 | — | — | 1 | ||
| Dyslipidemias | D050171 | HP_0003119 | — | — | 1 | — | — | 1 | |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | 1 | — | — | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | 1 | — | — | 1 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 7 | 1 | — | — | 5 | 12 | ||
| Depression | D003863 | F33.9 | 1 | 1 | — | — | 8 | 9 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | 5 | 8 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | — | — | 5 | 6 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 2 | 1 | — | — | — | 3 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | — | 2 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | 2 | 3 |
| Cognitive dysfunction | D060825 | G31.84 | 1 | 2 | — | — | — | 2 | |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | — | — | 1 | 2 |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | 1 | — | — | 1 | 2 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 1 | — | — | — | 2 | 3 | ||
| Squamous cell carcinoma of head and neck | D000077195 | 1 | — | — | — | 2 | 3 | ||
| Harm reduction | D040261 | 3 | — | — | — | — | 3 | ||
| Prostatic neoplasms | D011471 | C61 | 1 | — | — | — | 1 | 2 | |
| Colorectal neoplasms | D015179 | 1 | — | — | — | 1 | 2 | ||
| Cognition disorders | D003072 | 2 | — | — | — | — | 2 | ||
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 2 | — | — | — | — | 2 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | 1 | 2 |
| Nasopharyngeal neoplasms | D009303 | 1 | — | — | — | — | 1 | ||
| Cannabis | D002188 | 1 | — | — | — | — | 1 |
Show 14 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anesthesia | D000758 | — | — | — | — | 5 | 5 | ||
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 4 | 4 |
| Heart disease risk factors | D000082742 | — | — | — | — | 3 | 3 | ||
| Coronary artery disease | D003324 | I25.1 | — | — | — | — | 3 | 3 | |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | — | 2 | 2 |
| Psychological distress | D000079225 | — | — | — | — | 2 | 2 | ||
| Colonic neoplasms | D003110 | C18 | — | — | — | — | 2 | 2 | |
| Feeding behavior | D005247 | — | — | — | — | 2 | 2 | ||
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 2 | 2 |
| Suicide | D013405 | — | — | — | — | 2 | 2 |
Show 70 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NICOTINE |
| INN | — |
| Description | (S)-nicotine is a 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum. It has a role as a phytogenic insecticide, a teratogenic agent, a neurotoxin, an anxiolytic drug, a nicotinic acetylcholine receptor agonist, a biomarker, an immunomodulator, a mitogen, a peripheral nervous system drug, a psychotropic drug, a plant metabolite and a xenobiotic. It is a conjugate base of a (S)-nicotinium(1+). It is an enantiomer of a (R)-nicotine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCC[C@H]1c1cccnc1 |
Target
Agency Approved
No data
Alternate
TRPA1
TRPA1
P2RY11
P2RY11
HCAR1
HCAR1
CHRNA4
CHRNA4
HCAR2
HCAR2
TRPM2
TRPM2
KCND3
KCND3
CHRNA9
CHRNA9
HCAR3
HCAR3
CHRNA10
CHRNA10
CHRNA3
CHRNA3
Organism
Homo sapiens
Gene name
TRPA1
Gene synonyms
ANKTM1
NCBI Gene ID
Protein name
transient receptor potential cation channel subfamily A member 1
Protein synonyms
ankyrin-like with transmembrane domains 1, Ankyrin-like with transmembrane domains protein 1, p120, Transformation-sensitive protein p120, Wasabi receptor
Uniprot ID
Mouse ortholog
Trpa1 (277328)
transient receptor potential cation channel subfamily A member 1 (Q8BLA8)
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
|---|---|---|---|---|
| VCV000017497 | CHRNA5, 1192G>A, Asp398Asn | drug response | 2021-03-24 | 2B |
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 113,003 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,336 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more